474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity

• Published in: Journal for immunotherapy of cancer Vol. 10; no. Suppl 2; p. A494
• Main Authors: Obeidat, Akram, Atieh, Anas, Vitenshtein, Alon, Cinamon, Guy, Paz, Keren, Roviš, Tihana, Brilc, Paola, Hirsl, Lea, Mandelboim, Ofer, Jonjic, Stipan, Pini Tsukerman
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.11.2022
• Subjects: Immunotherapy; Tumors

BackgroundPoliovirus receptor (PVR, CD155) is a novel oncology target, differentially overexpressed in a wide range of solid tumors, which recently emerged as a main resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies functi...